Travere Therapeutics, Inc. (NASDAQ:TVTX)
| Market Cap | $4.51B+31.3% |
| Revenue (ttm) | $651.03M+49.4% |
| Net Income | -$121.51M-37.2% |
| EPS | -$1.56-43.1% |
| Shares Out | 95.99M |
| PE Ratio | n/a |
| Forward PE | 15.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,329,582 |
| Open | $48.09 |
| Previous Close | $48.30 |
| Day's Range | $46.93 - $49.29 |
| 52-Week Range | $22.59 - $68.73 |
| Beta | 1.12 |
| Analysts | Buy |
| Price Target | $76.00(+61.70%) |
| Earnings Date | Feb 18, 2027 |
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
6 firms rating TVTX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 18, 2027Earnings report
$TVTX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TVTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TVTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TVTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TVTX Revenue by Segment
| FILSPARI | $200.19M | 90.92% |
| Tiopronin products | $20.00M | 9.08% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TVTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TVTX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TVTX
| VTIVanguard Morningstar Total Stock Market ETF | $118.98M |
| IWMiShares Russell 2000 ETF | $112.70M |
| XBIState Street SPDR S&P Biotech ETF | $110.47M |
| VXFVanguard Extended Market ETF | $53.91M |
| VBVanguard Morningstar Small-Cap ETF | $53.20M |
| IWOiShares Russell 2000 Growth ETF | $40.74M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from TVTX’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-37.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| LFSC | F/M Emerald Life Sciences Innovation ETF | 5.67% |
| SBIO | ALPS Medical Breakthroughs ETF | 3.17% |
| HELX | Franklin Genomic Advancements ETF | 2.41% |
| PJP | Invesco Pharmaceuticals ETF | 2.34% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 2.08% |
| AFSC | abrdn Focused U.S. Small Cap Active ETF | 1.66% |
| TDNA | T. Rowe Price Biotech ETF | 1.39% |
| CTAG | Calamos Timpani Active SMID Growth ETF | 1.36% |
| MMSC | First Trust Multi-Manager Small Cap Opportunities ETF | 1.30% |
| BBP | Virtus Biotech ETF | 1.29% |
| SPIT | F/m Emerald Special Situations ETF | 1.25% |
| XBI | State Street SPDR S&P Biotech ETF | 1.17% |
Weight is the stock’s share of each fund’s holdings.
